Lethargic Depression Study

Summary

This is a study of Major Depressive Disorder (MDD) in patients with decreased energy, pleasure and interests.

Timeline

Start

2003-06

Primary completion

2005-05

Completion

2005-05

Outcome

Met primary endpoint

paper Bupropion XL was superior to placebo at endpoint in reducing the IDS-IVR-30 total score (p = .018) PMID 16848645 ↗

Publications

• Results Rush J, VanMeter SA, Wightman D, Hampton KD, Krishen A, Modell JG. Wellbutrin XL for the treatment of adults with major depressive disorder. American Psychiatric Association 158th Annual Meeting, Atlanta, GA, 21-26 May, 2005, Abstract No. 787.
• Results Jefferson JW, Rush AJ, Nelson JC, VanMeter SA, Krishen A, Hampton KD, Wightman DS, Modell JG. Extended-release bupropion for patients with major depressive disorder presenting with symptoms of reduced energy, pleasure, and interest: findings from a randomized, double-blind, placebo-controlled study. J Clin Psychiatry. 2006 Jun;67(6):865-73. doi: 10.4088/jcp.v67n0602.
• Results Rush J, VanMeter SA, Wightman DS, Hampton KD, Krishen A, Modell JG. Bupropion XL for the treatment of adults with major depressive disorder. 45th Annual New Clinical Drug Evaluation Unit (NCDEU) Meeting, Boca Raton, FL, 6-9June, 2005.

Drugs

Indications